HALO News and Press, Halozyme Therapeutics Inc.

2024-07-01 10:02:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, w...

2024-06-25 06:36:05 ET More on Halozyme Therapeutics Halozyme Therapeutics: The Story Brightens Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript Halozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Bristol Myers Opdivo...

Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis PR Newswire OCREVUS ® subcutaneous (SC) injection offers a new 10-minute administration with comparable effica...

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire VYVGART® Hytrulo is the first and only neonatal Fc receptor (FcRn) blocker that is delivered as...

2024-06-21 07:25:03 ET More on Bristol-Myers Squibb Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least Bristol-Myers Squibb: Could This Be A Value Trap? (Technical Analysis) Bristol-Myers Squibb Company (BMY) Goldman Sachs 45th Annual Global Healthca...

2024-06-07 10:32:06 ET Summary Halozyme Therapeutics, Inc. raised both its full year 2024 financial guidance and 5-year financial outlook on Thursday, sending the stock 12% higher. Halozyme Therapeutics continues to execute well, is buying back a significant amount of its own stoc...

2024-06-07 09:16:13 ET More on Halozyme Therapeutics Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript Halozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics ...

2024-06-07 07:15:04 ET H.C. Wainwright analyst issues BUY recommendation for HALO on June 7, 2024 06:06AM ET. The previous analyst recommendation was Buy. HALO was trading at $51.44 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...

2024-06-07 06:00:08 ET Joseph Catanzaro from Piper Sandler issued a price target of $51.00 for HALO on 2024-06-07 05:25:00. The adjusted price target was set to $51.00. At the time of the announcement, HALO was trading at $51.44. The overall price target consensus is at ...

2024-06-06 21:15:02 ET Piper Sandler analyst issues NEUTRAL recommendation for HALO on June 6, 2024 07:30PM ET. The previous analyst recommendation was Overweight. HALO was trading at $51.44 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...